ONC
BeOne Medicines AG · Healthcare · Biotechnology
Momentum inputs (comparable managers):
holder breadth -6.7% ·
share flow -0.5% ·
net new positions -7.1%
· formula
Broad distribution: falling shares and fewer holders
All ownership figures: tracked 13F managers only, common-stock positions, reporting period Q3 2025
| Quarter | Holders | Δ | Shares | Reported value | New | Exits |
|---|---|---|---|---|---|---|
| Q2 2026 | 93 | -6 | 22.51M | $6.43B | +4 | −10 |
| Q1 2026 | 100 | +2 | 21.59M | $6.42B | +8 | −6 |
| Q4 2025 | 97 | +2 | 20.58M | $6.25B | +2 | n/a |
| Q3 2025 | 14 | -1 | 11.95M | $4.07B | +1 | −2 |
| Q2 2025 | 12 | -4 | 11.51M | $2.79B | +1 | −5 |
| Q1 2025 | 14 | +4 | 13.65M | $3.71B | +4 | n/a |
| Q4 2024 | 10 | +1 | 12.37M | $2.28B | +1 | n/a |
| Q3 2024 | 9 | +1 | 12.34M | $2.77B | +1 | n/a |
| Q2 2024 | 8 | n/a | 11.43M | $1.63B | n/a | n/a |
| # | Manager | Shares | Δ shares | Value | Their weight | Held | ||
|---|---|---|---|---|---|---|---|---|
| 1 | PRIMECAP Management ✦ | 5.08M | -0.1% | $1.73B | 1.3% | ▼ Trim | 6 | SEC ↗ |
| 2 | Fidelity (FMR) ✦ | 3.78M | +9.7% | $1.29B | 0.1% | ▲ Add | 2 | SEC ↗ ×5 |
| 3 | T. Rowe Price ✦ | 1.63M | +59.8% | $555.54M | 0.1% | ▲ Add | 6 | SEC ↗ ×2 |
| 4 | BlackRock ✦ (passive) | 496.09K | -1.0% | $169.02M | 0.0% | ▼ Trim | 2 | SEC ↗ ×14 |
| 5 | Morgan Stanley ✦ | 353.29K | n/a | $120.37M | 0.0% | n/c | 1 | SEC ↗ ×9 |
| 6 | Marshall Wace ✦ | 312.44K | -33.2% | $106.45M | 0.1% | ▼ Trim | 6 | SEC ↗ ×4 |
| 7 | JPMorgan Chase ✦ | 97.62K | n/a | $33.26M | 0.0% | n/c | 1 | SEC ↗ ×16 |
| 8 | Arrowstreet Capital ✦ | 55.73K | +2573.1% | $18.99M | 0.0% | ▲ Add | 3 | SEC ↗ |
| 9 | Goldman Sachs Group ✦ | 44.23K | n/a | $15.07M | 0.0% | n/c | 1 | SEC ↗ ×2 |
| 10 | Citadel Advisors ✦ | 36.20K | -93.3% | $12.34M | 0.0% | ▼ Trim | 6 | SEC ↗ ×2 |
| 11 | Geode Capital Management ✦ (passive) | 29.15K | -18.2% | $9.93M | 0.0% | ▼ Trim | 6 | SEC ↗ |
| 12 | Millennium Management ✦ | 17.85K | -91.1% | $6.08M | 0.0% | ▼ Trim | 6 | SEC ↗ |
| 13 | State Street Global Advisors ✦ (passive) | 8.79K | -36.2% | $2.99M | 0.0% | ▼ Trim | 2 | SEC ↗ |
| 14 | Baillie Gifford ✦ | 8 | New | $2,726 | 0.0% | New | 1 | SEC ↗ |
“Their weight” = the position's share of that manager's reported 13F equity value: the conviction measure. ✦ = curated manager.
New buyers
| Baillie Gifford | $2,726 | 0.0% |
Exited
| D. E. Shaw & Co. | $38.30M | was 0.0% |
| Adage Capital Partners | $9.44M | was 0.0% |
Full-market context: across ALL 13F filers (SEC structured data, Q1 2026): 278 holders, 34.74M shares, $10.13B reported. This is a different, older period than the tracked-universe figures above and the two are never mixed.
What else this security's tracked holders most often hold: shared-ownership counts, not fundamental relationships.
Open-market purchases (P)
No open-market insider purchases in our coverage window.
Open-market sales (S)
Officer · 1.11K sh · $418,125
Director · 738 sh · $271,012
Director · 14.53K sh · $5.32M
Director · 2.05K sh · $748,891
Director · 3.42K sh · $1.24M
Director · 3.50K sh · $1.27M
Director · 4.24K sh · $1.54M
Director · 2.24K sh · $809,120
Director · 40 sh · $14,366
Director · 120 sh · $43,045
Awards, exercises and tax withholding are never counted as buys or sales here. Methodology
7.8% of class · View original SEC filing ↗
8.0% of class · View original SEC filing ↗